W Watford
Cardiovascular Disease · Birmingham, ALNPI 1326037920
Payments from drug & device makers
Across 129 payments — averaging $14.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$573
- Amgen$237
- Boehringer Ingelheim$186
- Johnson & Johnson$177
- Sanofi-aventis U.S. LLC$132
- Alnylam Pharmaceuticals Inc.$123
- plus $430 from 11 others
What the payments were for
- Food & beverage$1,860100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 44 | $573 |
| Amgen | 18 | $237 |
| Boehringer Ingelheim | 12 | $186 |
| Johnson & Johnson | 13 | $177 |
| Sanofi-aventis U.S. LLC | 8 | $132 |
| Alnylam Pharmaceuticals Inc. | 7 | $123 |
| E.r. Squibb & Sons, L.L.C. | 6 | $86 |
| Pfizer | 5 | $75 |
| Amarin Pharma, Inc. | 5 | $71 |
| Esperion Therapeutics, Inc. | 3 | $70 |
| Boston Scientific | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
| Merck | 1 | $12 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$1,860 in reported general payments places this provider in the 35th percentile of 292 cardiovascular disease providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 28 | $22,147 |
| EliquisApixaban | 11 | $12,642 |
| Potassium Chloride | 12 | $701 |
| Atorvastatin Calcium | 17 | $517 |
| Metoprolol Succinate | 11 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $75 | $12,64211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Birmingham
- Mustafa AhmedBirmingham$2.5M
- Alain BouchardBirmingham$1.9M
- Steven JonesBirmingham$1M
- Pankaj AroraBirmingham$889K
- Vikram AroraBirmingham$810K
- Robert BourgeBirmingham$590K
- Hutton BrantleyBirmingham$316K
- Thomas CawthonBirmingham$306K
- William RogersBirmingham$264K
- Farrell MendelsohnBirmingham$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.